PINK1 and head and neck cancer: In particular, deletion of PINK1 was associated with substantially lower levels of six immune infiltrates in breast invasive carcinoma, colon adenocarcinoma, head and neck cancer, lower grade glioma, lung adenocarcinoma, lung squamous cell carcinoma, sarcoma, skin cutaneous melanoma, and stomach adenocarcinoma.